Gut-derived Neuropeptides in Cerebrospinal Fluid of Patients With Parkinson's Disease and Healthy Controls
Quantitative Analysis of Gut-derived Neuropeptides in Cerebrospinal Fluid (CSF) of Patients With Parkinson's Disease and Healthy Controls
Patrocinador principal: Dr. Marcus Unger
In previous work, the investigators analyzed the concentration of gut-derived peptides (ghrelin, pancreatic polypeptide [PP]) in serum of patients with Parkinson's disease (PD). The investigators have shown that the secretion pattern differs between PD patients and controls. Beside ghrelin and pancreatic polypeptide other gut-derived peptides (e.g. Glucagon-like-Peptide 1[GLP-1], Amylin, etc.) might be relevant for PD as well. The rational to investigate gut-derived peptides in the neurological disorder Parkinson's disease (PD) is based on the following considerations:
- Receptors for gut-derived peptides are expressed in Central Nervous System (CNS) structures that are affected by the neurodegenerative process underlying Parkinson's disease
- Gut-derived peptides are involved in the modulation of higher brain functions (mood, cognition, reward-related behaviour) that are frequently altered in Parkinson's disease.
- The secretion of gut peptides is (co-)regulated by the vagal nerve that is dysfunctional in Parkinson's disease.
- Certain gut-derived peptides (ghrelin, GLP-1) stimulate neurogenesis and might be able to prevent cell death in neurodegenerative disorders, including Parkinson's disease.
Collection of CSF and serum samples in a standardized way in order to quantitatively measure the concentration of gut-derived peptides (ghrelin, leptin, glucose-dependent insulinotropic peptide [GIP], GLP-1, amylin, PP, peptide YY [PYY], and insulin). Scientific questions:
1. Do CSF (and serum) concentrations of these gut peptides differ between PD patients and controls?
2. Do CSF (and serum) concentrations of the investigated peptides correlate with clinical and / or epidemiological characteristics of the investigated subjects (age, gender, BMI, disease duration, severity of motor impairments, presence of non-motor symptoms, co-morbidities, medication, etc.)?
|Fecha de inicio||January 2013|
|Fecha de Terminación||December 2015|
|Fecha de finalización primaria||December 2015|
|Tipo de estudio||Observational|
Método de muestreo: Non-Probability Sample
Main Inclusion Criteria: - Informed consent to participate - Capability to understand risks of study-related procedures - For PD cohort: diagnosis of (idiopathic) Parkinson's disease Main Exclusion Criteria: - Pregnancy - Subjects incompetent to provide informed consent - Subjects that cannot undergo a lumbar puncture for medical reasons (thrombocytopenia, anticoagulation, increased cranial pressure) - For control cohort: presence of a neurodegenerative disorder
Main Inclusion Criteria:
- Informed consent to participate
- Capability to understand risks of study-related procedures
- For PD cohort: diagnosis of (idiopathic) Parkinson's disease
Main Exclusion Criteria:
- Subjects incompetent to provide informed consent
- Subjects that cannot undergo a lumbar puncture for medical reasons (thrombocytopenia, anticoagulation, increased cranial pressure)
- For control cohort: presence of a neurodegenerative disorder
Edad mínima: 18 Years
Edad máxima: 75 Years
Voluntarios Saludables: Accepts Healthy Volunteers
|Fecha de verificación||
Afiliación del investigador: Saarland University
Nombre completo del investigador: Dr. Marcus Unger
Título del investigador: Consultant / Oberarzt der Klinik für Neurologie
|Tiene acceso ampliado||No|
|Grupo de brazo||
Etiqueta: Parkinson's disease
Descripción: Patients with Parkinson's disease
Descripción: Healthy controls
|Información de diseño del estudio||
Modelo de observación: Cohort
Perspectiva de tiempo: Prospective